Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease - PubMed (original) (raw)
Randomized Controlled Trial
. 2006 Oct;17(10):2928-36.
doi: 10.1681/ASN.2005101101. Epub 2006 Sep 7.
Affiliations
- PMID: 16959828
- PMCID: PMC3833081
- DOI: 10.1681/ASN.2005101101
Randomized Controlled Trial
Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease
Keith C Norris et al. J Am Soc Nephrol. 2006 Oct.
Abstract
Patients with chronic kidney disease have an increased risk for progression to ESRD. The purpose of this study was to examine factors that predict increased risk for adverse renal outcomes. Cox regression was performed to assess the potential of 38 baseline risk factors to predict the clinical renal composite outcome of 50% or 25-ml/min per 1.73 m(2) GFR decline or ESRD among 1094 black patients with hypertensive nephrosclerosis (GFR 20 to 65 ml/min per 1.73 m(2)). Patients were trial participants who had been randomly assigned to one of two BP goals and to one of three antihypertensive regimens and followed for a range of 3 to 6.4 yr. In unadjusted and adjusted analyses, baseline proteinuria was consistently associated with an increased risk for adverse renal outcomes, even at low levels of proteinuria. The relationship of proteinuria with adverse renal outcomes also was evident in analyses that were stratified by level of GFR, which itself was associated with adverse renal outcomes but only at levels <40 ml/min. Other factors that were significantly associated with increased renal events after adjustment for baseline GFR, age, and gender, both with and without adjustment for baseline proteinuria, included serum creatinine, urea nitrogen, and phosphorus. In black patients with hypertensive nephrosclerosis, increased proteinuria, reduced GFR, and elevated levels of serum creatinine, urea nitrogen and phosphorus were directly associated with adverse clinical renal events. These findings identify a subset of this high-risk population that might benefit from even more aggressive treatment.
Figures
Figure 1
Joint association of the renal composite (GFR event or ESRD) with baseline proteinuria and baseline GFR. Shown are hazard ratios of the renal composite (GFR event or ESRD) for the designated combinations of levels of baseline proteinuria (expressed as baseline urine protein/creatinine ratio) and baseline GFR, adjusting for age, gender, and randomized treatment groups. Both baseline factors are strongly predictive of the occurrence of a GFR event or ESRD after controlling for the other.
Figure 2
Association of composite outcomes with baseline factors, with and without adjustment for baseline proteinuria. Shown are the hazard ratios (with 95% confidence intervals [CI]) of two composite outcomes that are associated with 1-SD increases in the indicated baseline factors: (1) GFR event or ESRD and (2) GFR event, ESRD, or death. Results are provided both without adjustment for baseline proteinuria (CI indicated with solid lines) and then with adjustment for baseline proteinuria (CI indicated with dashed lines). All analyses are adjusted for age, gender, mean baseline GFR, and randomized treatment groups. S., serum; ECG, electrocardiogram; LVH, left ventricular hypertrophy; U., urine.
Similar articles
- Net endogenous acid production is associated with a faster decline in GFR in African Americans.
Scialla JJ, Appel LJ, Astor BC, Miller ER 3rd, Beddhu S, Woodward M, Parekh RS, Anderson CA; African American Study of Kidney Disease and Hypertension Study Group. Scialla JJ, et al. Kidney Int. 2012 Jul;82(1):106-12. doi: 10.1038/ki.2012.82. Epub 2012 Apr 4. Kidney Int. 2012. PMID: 22475819 Free PMC article. Clinical Trial. - The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.
Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL. Lea J, et al. Arch Intern Med. 2005 Apr 25;165(8):947-53. doi: 10.1001/archinte.165.8.947. Arch Intern Med. 2005. PMID: 15851648 Clinical Trial. - Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG; African American Study of Kidney Disease and Hypertension Study Group. Wright JT Jr, et al. JAMA. 2002 Nov 20;288(19):2421-31. doi: 10.1001/jama.288.19.2421. JAMA. 2002. PMID: 12435255 Clinical Trial. - Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria.
Mulè G, Castiglia A, Cusumano C, Scaduto E, Geraci G, Altieri D, Di Natale E, Cacciatore O, Cerasola G, Cottone S. Mulè G, et al. Adv Exp Med Biol. 2017;956:279-306. doi: 10.1007/5584_2016_85. Adv Exp Med Biol. 2017. PMID: 27873229 Review. - Proteinuria and hypertensive nephrosclerosis in African Americans.
Toto RD. Toto RD. Kidney Int Suppl. 2004 Nov;(92):S102-4. doi: 10.1111/j.1523-1755.2004.09224.x. Kidney Int Suppl. 2004. PMID: 15485398 Review.
Cited by
- Association of hyperphosphatemia with renal prognosis in patients with autosomal dominant polycystic kidney disease.
Nitta K, Kataoka H, Manabe S, Makabe S, Akihisa T, Ushio Y, Seki M, Tsuchiya K, Hoshino J, Mochizuki T. Nitta K, et al. Clin Exp Nephrol. 2024 Sep 25. doi: 10.1007/s10157-024-02568-6. Online ahead of print. Clin Exp Nephrol. 2024. PMID: 39322826 - High Protein Diets and Glomerular Hyperfiltration in Athletes and Bodybuilders: Is Chronic Kidney Disease the Real Finish Line?
de Lorenzo A, Bomback AS, Mihic N. de Lorenzo A, et al. Sports Med. 2024 Oct;54(10):2481-2495. doi: 10.1007/s40279-024-02086-1. Epub 2024 Aug 28. Sports Med. 2024. PMID: 39196487 Review. - The association of normal-range serum phosphorus with immunoglobulin A nephropathy progression: a retrospective cohort study.
An X, Ding L, Yang Y, Yang Z, Zhang Y, Bai F, Liu L, Shi W, Yang X. An X, et al. Int Urol Nephrol. 2024 Jan;56(1):275-282. doi: 10.1007/s11255-023-03678-y. Epub 2023 Jun 19. Int Urol Nephrol. 2024. PMID: 37336802 - The Usefulness of Calcium/Magnesium Ratio in the Risk Stratification of Early Onset of Renal Replacement Therapy.
Afonso R, Marques RC, Borges H, Cabrita A, Silva AP. Afonso R, et al. Diagnostics (Basel). 2022 Oct 12;12(10):2470. doi: 10.3390/diagnostics12102470. Diagnostics (Basel). 2022. PMID: 36292159 Free PMC article. - Serum phosphate and chronic kidney and cardiovascular disease: Phosphorus potential implications in general population.
Raikou VD. Raikou VD. World J Nephrol. 2021 Sep 25;10(5):76-87. doi: 10.5527/wjn.v10.i5.76. World J Nephrol. 2021. PMID: 34631478 Free PMC article. Review.
References
- Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444. - PubMed
- Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med. 2001;134:629–636. - PubMed
- Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002;13:745–753. - PubMed
- Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305. - PubMed
- US Renal Data System. USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2003
Publication types
MeSH terms
Substances
Grants and funding
- DK 2818-02/DK/NIDDK NIH HHS/United States
- 5M01 RR 00071/RR/NCRR NIH HHS/United States
- M01 RR 00827/RR/NCRR NIH HHS/United States
- P20 RR011104/RR/NCRR NIH HHS/United States
- M01 00032/PHS HHS/United States
- U01 DK065455/DK/NIDDK NIH HHS/United States
- M01 RR 00052/RR/NCRR NIH HHS/United States
- M01 RR000071/RR/NCRR NIH HHS/United States
- P20 RR011145/RR/NCRR NIH HHS/United States
- M01 RR 00080/RR/NCRR NIH HHS/United States
- M01 RR000052/RR/NCRR NIH HHS/United States
- P20 RR 11145/RR/NCRR NIH HHS/United States
- K24 DK002818/DK/NIDDK NIH HHS/United States
- P20 RR 11104/RR/NCRR NIH HHS/United States
- M01 RR000827/RR/NCRR NIH HHS/United States
- M01 RR000080/RR/NCRR NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical